Skip to main content

2 Result(s)

within Hematology Remove this filter Internal Medicine Remove this filter Jorge Cortes Remove this filter Article Remove this filter

and
Your search also matched 4 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

Include preview-only content

  1. Article

    Open Access

    Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

    Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, ...

    Elias Jabbour, Jane Apperley, Jorge Cortes, Delphine Rea, Michael Deininger… in Leukemia (2024)

    Download PDF (922 KB) View Article

  2. Article

    Open Access

    Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

    Talacotuzumab, a humanized anti-CD123 monoclonal antibody, was evaluated in combination with decitabine in elderly patients with acute myeloid leukemia (AML) not eligible for intensive chemotherapy. A multicen...

    Pau Montesinos, Gail J. Roboz, Claude-Eric Bulabois, Marion Subklewe… in Leukemia (2021)

    Download PDF (952 KB) View Article